Cislini Jeff

General Counsel Cislini sells 13,388 shares of RVMD at $70.14; stock down 1.0% from 52-week high, but up 88.8% in 90 days.

Cislini Jeff, General Counsel of Revolution Medicines, sold 13,388 shares for $939,007.54 at $70.14 on 2025-11-18, reducing holdings from 63,813 shares to 50,425 shares (a 21.0% reduction). The transaction occurred within 1.0% of the 52-week high of $70.58, during a period of strong momentum—the stock has gained 88.8% over the prior 90 days and 30.6% over the prior 30 days. This sale comes on the heels of a prior RVMD transaction on 2025-10-17 that also generated positive 30-day returns (+23.2%). However, the company's fundamentals show zero revenue in the latest quarter and a net loss of $305,206,000 for the fiscal year, with annual revenue growth of -100.0%. The timing proximity to the 52-week high and the substantial share reduction warrant attention to whether this reflects portfolio management in the context of elevated valuations or shifting conviction.

General Counsel sold 12,000 RVMD shares at $55.00; -19.2% stake reduction while stock up +41.1% in 90 days

Jeff Cislini, General Counsel of Revolution Medicines, sold 12,000 shares (valued at $660,000.00) at $55.00, reducing his holdings from 62,425 to 50,425 shares, a -19.2% reduction of his position. The transaction occurred near the 52-week high ($60.60), and the stock has appreciated +41.1% over the past 90 days and +24.0% over 30 days. This sale by a senior executive comes against a backdrop of deteriorating company fundamentals: zero quarterly revenue, a $-247.8M net loss most recently, and -100.0% annual revenue growth. The combination of substantial insider liquidation at an elevated price point, steep losses, and absent near-term revenue signals a potential structural challenge with the business trajectory that warrants investor scrutiny of the company's clinical development progress and capital position.